The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice.

Abstract in brief

• The study explores how the GLP1 analogue Exendin4 reduces the rewarding effects of psychostimulant drugs like amphetamine and cocaine in mice, likely by affecting the mesolimbic dopamine system which is involved in reward and addiction.
• Since GLP1 receptors are found in brain areas related to reward, such as the nucleus accumbens and ventral tegmental area, activating these receptors with Exendin4 can decrease drug-induced behaviors like increased movement, dopamine release, and conditioned place preference.
• The findings suggest that GLP1 signaling plays a role in drug reward and dependence, and since GLP1 drugs like exenatide and liraglutide are already used to treat type II diabetes, they could potentially be repurposed as treatments for drug addiction.]